...
....
Pharmaceutical
Biotechnology

> See specialized channels
Medical Devices & Diagnostics
> See specialized channels
Industrial
Biotechnology
> See specialized channels


  Join us

  Follow us on Twitter   Join our LinkedIn Group   Our Blog

Biotech News App
Provides access to the latest biotech press releases ...more

Android_Logo App Store RIM_Logo_small

Media Partnership:
Want to have your RSS feed integrated on our website? Contact us
RSS Feeds RSS Feeds
JoomlaWatch Stats 1.2.9 by Matej Koval
For Editors
Sign up for press releases
For Companies
Sign up for our newsletter
Back to PRESS RELEASES - 

Sticares InterACT Prolongs its French Research Tax Credit Approval

| Print |
Thursday, 27 January 2011 15:45 (UTC + 1)

sticares_logo

Rhoon, NL,  January 27, 2011 / b3c newswire / - Sticares InterACT has been awarded the French research tax credit approval since 2009 and this approval has now been extended also for the years 2011, 2012 and 2013. The approval will help our existing and future clients in France to take advantage of this R&D tax credit.

 

As a result of Sticares InterACT being listed as an “approved organization”, the French ministry will allow for significant refunds by any French R&D company on their spending on Sticares InterACT’s services. The research tax credit is either deducted from annual corporate tax, or reimbursed and is calculated on the basis of the amount ("volume") of R&D expenditure by the company in France.

 

 

About Sticares InterACT - www.sticaresinteract.com
Sticares InterACT is the contract research arm of the Sticares Cardiovascular Research Institute, an independent institute established in 1981 in the Netherlands. Sticares InterACT provides an extensive range of services including clinical project management, site management, medical monitoring, event management and pharmacovigilance to pharmaceutical, biotechnology and medical device companies. Sticares InterACT is currently present in 26 European countries with access to a broad network of investigators guaranteeing high patient recruitment rates, whilst world-wide coverage is provided by its GlobalACT partnership.

In addition, Sticares InterACT offers outstanding consultancy services through its Scientific Advisory Board and the Sticares Cardiovascular Research Institute. Sticares InterACT has been involved in many phase II-IV clinical trials in angina, acute coronary syndrome, secondary prevention of CAD, heart failure, hypertension, diabetes, hyperlipidemia and atherosclerosis and has successfully managed multinational landmark studies including EUROPA, HYVET, PREAMI, BEAUTIFUL and SHIFT.


Contact

Sticares InterACT

Oever 1-5

3161 GR Rhoon

The Netherlands

Office: +31 10 48 55 177